Proctor & Gamble
This article was originally published in The Rose Sheet
Executive Summary
Second quarter (ended Dec. 31) sales were flat (down .7%) at $7.79 bil., the firm announces Jan. 27. P&G noted that the slight decrease was due to the impact of unfavorable exchange rates; excluding that effect, sales would have increased 3%. In the first half, sales fell 2.3% to $15.35 bil. Net earnings advanced 13.4% to $653 mil. in the second quarter; they would have climbed 17% at constant exchange rates. P&G attributed the gain to "strong U.S. and international unit volume growth and lower costs." Excluding the discontinued pulp and juice operations, unit volume advanced 6%. Eliminating the impact of charges for discontinued operations and the adoption of new accounting standards on fiscal 1993 first half net earnings, six-month net earnings were up 11.6% to $1.32 bil
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.